Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Coave Therapeutics S.A.
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Sep 22, 2023
Management Tracks
Shields leaving BenevolentAI as CEO
Plus: Berns named interim CMO at Faron, and updates from Coave, Maxion, Nanoscope and Patient Square
BioCentury | May 20, 2022
Discovery & Translation
Optimizing CNS tropism for AAVs at ASGCT
Directed evolution, genetic library screening and peptide modifications were the most common strategies presented
BioCentury | Nov 16, 2021
Management Tracks
End of an era at Biogen as R&D head Sandrock readies to retire
Plus: Levin-Allerhand joins Flagship, and updates from Alchemab, Agios, Actym, Gilgamesh and more
BioCentury | Sep 30, 2021
Product Development
Gaucher disease pipeline: Data Byte
Three clinical and 11 preclinical candidates move beyond traditional enzyme replacement, aim for wider range of patients
Items per page:
1 - 5 of 5